Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 15;40(38):5631–5640. doi: 10.1016/j.vaccine.2022.08.018

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Longitudinal changes of the anti-RBD antibody titers among all participants. (a) Scatterplot of participant antibody titers at each time point according to the Architect assay; (b) Scatterplot of participant antibody titers at each time point according to the Elecsys assay; (c) GMT (95 % CI) and GMT ratio (95 % CI) of antibody titers over time after the first vaccination according to the Architect assay; (d) GMT (95 % CI) and GMT ratio (95 % CI) of antibody titers over time after the first vaccination according to the Elecsys assay. BMI: body mass index; CI: confidence interval; anti-RBD: anti-SARS-CoV-2 receptor binding domain spike protein IgG; GMT: geometric mean titer; Architect: Architect SARS-CoV-2 IgG Ⅱ Quant (Abbott Laboratories); Elecsys: Elecsys anti-SARS-CoV-2 S (Roche Diagnostics); S0: Within 1 week before the first vaccination, S1: Within 1 week before the second vaccination, S2: 4–5 weeks after the second vaccination, and S3: 6 months after the second vaccination.